Last Updated : January 17, 2025
Details
Generic Name:
mirikizumab
Project Status:
Pending
Therapeutic Area:
Crohn’s disease
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Omvoh
Project Line:
Reimbursement Review
Project Number:
SR0880-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Eli Lilly Canada Inc. requests that Omvoh (mirikizumab) be funded as per the anticipated Health Canada indication.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Omvoh (mirikizumab) is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 17, 2025